Randomized, controlled trial of glucose-sparing peritoneal dialysis in diabetic patients

Journal of the American Society of Nephrology

Volumn 24, Issue 11, 2013, Pages 1889-1900

  Li, Philip K T ^a   Culleton, Bruce F ^b   Ariza, Amaury ^c   Do, Jun Young ^d   Johnson, David W ^e   Sanabria, Mauricio ^b   Shockley, Ty R ^b   Story, Ken ^b   Vatazin, Andrey ^f   Verrelli, Mauro ^g   Yu, Alex W ^h,i   Bargman, Joanne M ^j  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b BAXTER HEALTHCARE CORPORATION   (United States)

^c RTS Ltda Cartagena   (Colombia)

^d Young Nam University Hospital   (South Korea)

^e UNIVERSITY OF QUEENSLAND   (Australia)

^f M F VLADIMIRSKY MOSCOW REGIONAL RESEARCH CLINICAL INSTITUTE   (Russian Federation)

^g ST BONIFACE GENERAL HOSPITAL   (Canada)

^h Baxter Healthcare Ltd   (Hong Kong)

ⁱ ALICE HO MIU LING NETHERSOLE HOSPITAL   (Hong Kong)

^j TORONTO GENERAL HOSPITAL   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; APOLIPOPROTEIN; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; ICODEXTRIN; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; EXTRACELLULAR SPACE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; OUTCOME ASSESSMENT; PERITONEAL DIALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 84887039338     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2012100987     Document Type: Article

References (44)

1. Mehrotra R, Chiu YW, Kalantar-Zadeh K, Bargman J., Vonesh E: Similar outcomes with hemodialysis and peritoneal dialysis in patients with end-stage renal disease. Arch Intern Med 171: 110-118, 2011
2. Li PK, Szeto CC: Success of the peritoneal dialysis programme in Hong Kong. Nephrol Dial Transplant 23: 1475-1478, 2008 (Pubitemid 351767799)
3. Boateng EA, East L: The impact of dialysis modality on quality of life: A systematic review. J Ren Care 37: 190-200, 2011
4. Zhang AH, Cheng LT, Zhu N, Sun L.H., Wang T: Comparison of quality of life and causes of hospitalization between hemodialysis and peritoneal dialysis patients in China. Health Qual Life Outcomes 5: 49, 2007
5. Roberts MA, Polkinghorne KR, McDonald S.P., Ierino FL: Secular trends in cardiovascular mortality rates of patients receiving dialysis compared with the general population. Am J Kidney Dis 58: 64-72, 2011
6. Weinhandl ED, Foley RN, Gilbertson D.T., Arneson TJ, Snyder JJ, Collins AJ: Propensity-matched mortality comparison of incident hemodialysis and peritoneal dialysis patients. J Am Soc Nephrol 21: 499-506, 2010
7. Mehrotra R: Comparing outcomes of hemodialysis and peritoneal dialysis patients: Consider the pitfalls. Contrib Nephrol 178: 30-34, 2012
8. Krediet RT, Balafa O: Cardiovascular risk in the peritoneal dialysis patient. Nat Rev Nephrol 6: 451-460, 2010
9. Li PK, Chow KM: The clinical and epidemiological aspects of vascular mortality in chronic peritoneal dialysis patients. Perit Dial Int 25[Suppl 3]: S80-S83, 2005 (Pubitemid 40883223)
10. Holmes CJ: Reducing cardiometabolic risk in peritoneal dialysis patients: Role of the dialysis solution. J Diabetes Sci Tech 3: 1472-1480, 2009
11. Burkart J: Metabolic consequences of peritoneal dialysis. Semin Dial 17: 498-504, 2004 (Pubitemid 40110436)
12. Johnson DW, Armstrong K, Campbell S.B., Mudge DW, Hawley CM, Coombes JS, Prins J.B., Isbel NM: Metabolic syndrome in severe chronic kidney disease: Prevalence, predictors, prognostic significance and effects of risk factor modification. Nephrology (Carlton) 12: 391-398, 2007 (Pubitemid 47075413)
13. Li PK, Kwan BC, Ko G.T., Chow KM, Leung CB, Szeto CC: Treatment of metabolic syndrome in peritoneal dialysis patients. Perit Dial Int 29 [Suppl 2]: S149-S152, 2009
14. Duong U, Mehrotra R, Molnar M.Z., Noori N., Kovesdy CP, Nissenson AR, Kalantar-Zadeh K: Glycemic control and survival in peritoneal dialysis patients with diabetes mellitus. Clin J Am Soc Nephrol 6: 1041-1048, 2011
15. Dheir H, Ozkahya M, Kircelli F., Sezis Demirci M, Asci G, Toz H., Ertilav M, Kose T, Ok E: Glycosylated hemoglobin levels are associated with cardiovascular events in nondiabetic peritoneal dialysis patients. J Nephrol 25: 107-112, 2012
16. Paniagua R, Ventura MD, Avila-Díaz M, Cisneros A, Vicenté-Martínez M, Furlong MD, García-González Z, Villanueva D, Orihuela O, Prado-Uribe MD, Alcántara G, Amato D: Icodextrin improves metabolic and fluid management in high and high-average transport diabetic patients. Perit Dial Int 29: 422-432, 2009
17. Martikainen T, Teppo AM, Gronhagen-Riska C, Ekstrand A: Benefit of glucose-free dialysis solutions on glucose and lipid metabolism in peritoneal dialysis patients. Blood Purif 23: 303-310, 2005 (Pubitemid 41327802)
18. Marshall J, Jennings P, Scott A., Fluck RJ, McIntyre CW: Glycemic control in diabetic CAPD patients assessed by continuous glucose monitoring system (CGMS). Kidney Int 64: 1480-1486, 2003 (Pubitemid 37153816)
19. Johnson DW, Arndt M, O'Shea A, Watt R, Hamilton J., Vincent K: Icodextrin as salvage therapy in peritoneal dialysis patients with refractory fluid overload. BMC Nephrol 2: 2, 2001
20. Amici G, Orrasch M, Da Rin G, Bocci C: Hyperinsulinism reduction associated with icodextrin treatment in continuous ambulatory peritoneal dialysis patients. Adv Perit Dial 17: 80-83, 2001
21. Furuya R, Odamaki M, Kumagai H., Hishida A: Beneficial effects of icodextrin on plasma level of adipocytokines in peritoneal dialysis patients. Nephrol Dial Transplant 21: 494-498, 2006 (Pubitemid 43160008)
22. Gürsu E.M., Ozdemir A, Yalinbas B., Gürsu RU, Canbakan M., Güven B, Atasoyu E.M., Keskin AT, Elçi A, Baru Y: The effect of icodextrin and glucose-containing solutions on insulin resistance in CAPD patients. Clin Nephrol 66: 263-268, 2006 (Pubitemid 44541213)
23. Canbakan M, Sahin GM: Icodextrine and insulin resistance in continuous ambulatory peritoneal dialysis patients. Ren Fail 29: 289-293, 2007 (Pubitemid 46752341)
24. Takatori Y, Akagi S, Sugiyama H., Inoue J, Kojo S, Morinaga H., Nakao K, Wada J, Makino H: Icodextrin increases technique survival rate in peritoneal dialysis patients with diabetic nephropathy by improving body fluid management: A randomized controlled trial. Clin J Am Soc Nephrol 6: 1337-1344, 2011
25. Hanas R, John G; International HbA Consensus Committee: 2010 consensus statement on the worldwide standardization of the hemoglobin A1c measurement. Diabet Med 27: 737-738, 2010
26. Inaba M, Okuno S, Kumeda Y., Yamada S, Imanishi Y, Tabata T., Okamura M, Okada S, Yamakawa T., Ishimura E, Nishizawa Y; Osaka CKD Expert Research Group: Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: Effect of anemia and erythropoietin injection. J Am Soc Nephrol 18: 896-903, 2007 (Pubitemid 46434506)
27. Peacock TP, Shihabi ZK, Bleyer A.J., Dolbare EL, Byers JR, Knovich MA, Calles-Escandon J, Russell G.B., Freedman BI: Comparison of glycated albumin and hemoglobin A(1c) levels in diabetic subjects on hemodialysis. Kidney Int 73: 1062-1068, 2008 (Pubitemid 351543905)
28. Shurraw S, Majumdar SR, Thadhani R, Wiebe N., Tonelli M; Alberta Kidney Disease Network: Glycemic control and the risk of death in 1,484 patients receiving maintenance hemodialysis. Am J Kidney Dis 55: 875-884, 2010
29. Wu MS, Yu CC, Yang C.W., Wu CH, Haung JY, Hong JJ, Fan Chiang CY, Huang CC, Leu ML: Poor pre-dialysis glycaemic control is a predictor of mortality in type II diabetic patients on maintenance haemodialysis. Nephrol Dial Transplant 12: 2105-2110, 1997
30. Kalantar-Zadeh K., Kopple JD, Regidor D.L., Jing J., Shinaberger CS, Aronovitz J, McAllister CJ, Whellan D, Sharma K: A1C and survival in maintenance hemodialysis patients. Diabetes Care 30: 1049-1055, 2007 (Pubitemid 46684623)
31. Williams ME, Lacson E Jr, Wang W, Lazarus JM, Hakim R: Glycemic control and extended hemodialysis survival in patients with diabetes mellitus: Comparative results of traditional and time-dependent Cox model analyses. Clin J Am Soc Nephrol 5: 1595-1601, 2010
32. Drechsler C, Krane V, Ritz E., März W, Wanner C: Glycemic control and cardiovascular events in diabetic hemodialysis patients. Circulation 120: 2421-2428, 2009
33. Wu MS, Yu CC, Wu C.H., Haung JY, Leu ML, Huang CC: Pre-dialysis glycemic control is an independent predictor of mortality in type II diabetic patients on continuous ambulatory peritoneal dialysis. Perit Dial Int 19[Suppl 2]: S179-S183, 1999
34. Sekercioglu N, Dimitriadis C, Pipili C., Elias RM, Kim J, Oreopoulos DG, Bargman JM: Glycemic control and survival in peritoneal dialysis patients with diabetes mellitus. Int Urol Nephrol 44: 1861-1869, 2012
35. Quaschning T, Krane V, Metzger T., Wanner C: Abnormalities in uremic lipoprotein metabolism and its impact on cardiovascular disease. Am J Kidney Dis 38[Suppl 1]: S14-S19, 2001 (Pubitemid 32927605)
36. Sniderman A, Cianflone K, Kwiterovich PO Jr, Hutchinson T, Barre P, Prichard S: Hyperapobetalipoproteinemia: The major dyslipoproteinemia in patients with chronic renal failure treated with chronic ambulatory peritoneal dialysis. Atherosclerosis 65: 257-264, 1987 (Pubitemid 17073853)
37. Sierra-Johnson J., Fisher RM, Romero-Corral A, Somers V.K., Lopez-Jimenez F, Ohrvik J, Walldius G., Hellenius ML, Hamsten A: Concentration of apolipoprotein B is comparable with the apolipoprotein B/apolipoprotein A-I ratio and better than routine clinical lipid measurements in predicting coronary heart disease mortality: Findings from a multi-ethnic US population. Eur Heart J 30: 710-717, 2009
38. Vaziri ND, Norris K: Lipid disorders and their relevance to outcomes in chronic kidney disease. Blood Purif 31: 189-196, 2011
39. März W., Scharnagl H, Winkler K., Tiran A, Nauck M, Boehm B.O., Winkelmann BR: Low-density lipoprotein triglycerides associated with low-grade systemic inflammation, adhesion molecules, and angiographic coronary artery disease: The Ludwigshafen Risk and Cardiovascular Health study. Circulation 110: 3068-3074, 2004 (Pubitemid 39492000)
40. Rivera JJ, Nasir K, Campbell C., Carvalho JA, Blumenthal RS, Santos RD: Relation of plasma lipoprotein levels with low-grade inflammation in white men without clinical evidence of myocardial ischemia. Am J Cardiol 100: 450-454, 2007 (Pubitemid 47094694)
41. Davies SJ, Woodrow G, Donovan K., Plum J, Williams P, Johansson A.C., Bosselmann HP, Heimbürger O, Simonsen O., Davenport A, Tranaeus A, Divino Filho JC: Icodextrin improves the fluid status of peritoneal dialysis patients: Results of a double-blind randomized controlled trial. J Am Soc Nephrol 14: 2338-2344, 2003 (Pubitemid 37052381)
42. Wolfson M, Piraino B, Hamburger R.J., Morton AR; Icodextr in Study Group: A randomized controlled trial to evaluate the efficacy and safety of icodextrin in peritoneal dialysis. Am J Kidney Dis 40: 1055-1065, 2002 (Pubitemid 35265487)
43. Williams JD, Topley N, Craig K.J., Mackenzie RK, Pischetsrieder M, Lage C, Passlick-Deetjen J; Euro Balance Trial Group: The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 66: 408-418, 2004 (Pubitemid 38870119)
44. le Poole C.Y., Welten AG, ter Wee PM, Paauw NJ, Djorai AN, Valentijn RM, Beelen R.H., van den Born J, van Ittersum FJ: A peritoneal dialysis regimen low in glucose and glucose degradation products results in increased cancer antigen 125 and peritoneal activation. Perit Dial Int 32: 305-315, 2012